<DOC>
	<DOC>NCT00419068</DOC>
	<brief_summary>The purpose of this study is to determine whether vitamin D enhances response to standard antibiotic treatment for pulmonary tuberculosis.</brief_summary>
	<brief_title>Trial of Adjunctive Vitamin D in Tuberculosis Treatment</brief_title>
	<detailed_description />
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Tuberculosis, Pulmonary</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>Suspected smear positive pulmonary tuberculosis. Age 18 years or older. Written informed consent to participate. Known intolerance of vitamin D or firstline antituberculous therapy. Taking antituberculous therapy for more than six days in the six months preceding enrolment. Taking the following medication in the month preceding enrolment: oral corticosteroid therapy, immunosuppressant therapy or cytotoxic therapy. Taking the following medication at enrolment: benzothiadiazine derivatives, cardiac glycosides or antituberculous therapy other than rifampicin, isoniazid, pyrazinamide and ethambutol. Diagnosis of any of the following: sarcoidosis, hyperparathyroidism, nephrolithiasis, pulmonary silicosis, HIV infection, liver failure, renal failure or malignancy Infection with rifampicinresistant organism (as demonstrated by rapid molecular testing) Biochemical disturbance at enrolment: serum corrected calcium &gt;2.66 mmol/l, serum AST &gt;120 IU/l, total serum bilirubin &gt; 40 micromol/l or serum creatinine &gt; 250 micromol/l Breastfeeding or pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
</DOC>